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Examination of Mutations in BRAF, NRAS, and PTEN
in Primary Cutaneous Melanoma
Vikas K. Goel1,2,5, Alexander J.F. Lazar2,3,5,6, Carla L. Warneke4, Mark S. Redston2,3 and Frank G. Haluska1,2
Frequent somatic mutation of v-raf murine sarcoma viral oncogene homolog B (BRAF), a downstream effector
of the rat sarcoma oncogene (RAS) signaling pathway, is described in melanoma and other tumors. Our analysis
of melanoma cell lines suggests that activating mutations in BRAF can occur simultaneously with inactivation of
phosphatase and tensin homolog (PTEN), but neuroblastoma RAS (NRAS) mutations are not coincident. We
determined the concurrent prevalence of mutations in BRAF and NRAS, and alteration of PTEN expression in 69
primary cutaneous melanomas. BRAF mutations were seen in 57% of cases. NRAS was mutated in 17% of
samples, exclusively in exon 2. Two cases showed concurrent BRAF and NRAS mutations. Using
immunohistochemistry, PTEN protein expression was lost or greatly reduced in 19% of tumors. Seven tumors
with reduced PTEN yielded DNA amenable to sequencing, and three also showed mutation in BRAF but none in
NRAS. In all, 11 (85%) of 13 tumors showing reduced PTEN expression were greater than 3.5 mm thick, and the
association of increasing Breslow thickness and loss or reduction of PTEN expression was statistically significant
(Po0.0001). Mutations in NRAS were not coincident with reduced PTEN expression, and the concurrent
mutation of NRAS and BRAF was rare.
Journal of Investigative Dermatology (2006) 126, 154–160. doi:10.1038/sj.jid.5700026
INTRODUCTION
Cutaneous melanoma is an aggressive malignancy with
complex genetic etiology and advanced disease is generally
resistant to medical treatment (Haluska and Multani, 1999).
In other tumor types, the success of small-molecule kinase
inhibitors has underscored the relationship between somatic
tumor-specific mutations and therapy, and the promise of
developing new targeted therapies for the treatment of
melanoma has focused intense interest on understanding
the genetic contributors to melanomagenesis. Evidence
shows that the tumor suppressor genes CDKN2A (p16) and
phosphatase and tensin homolog (PTEN), along with the
oncogene neuroblastoma rat sarcoma oncogene (NRAS),
are involved in melanoma biology (Haluska and Hodi, 1998;
Wu et al., 2003; Daniotti et al., 2004). More recently,
mutations in v-raf murine sarcoma viral oncogene homolog
B (BRAF), a serine–threonine kinase and potential oncogene,
have been implicated in the majority of cases of melanoma
(Davies et al., 2002).
While mutations in BRAF are noted in up to 80% of
primary cutaneous melanoma samples, BRAF is also mutated
in the majority of benign melanocytic nevi (Brose et al., 2002;
Kumar et al., 2003; Maldonado et al., 2003; Sasaki et al.,
2004; Shinozaki et al., 2004; Thomas et al., 2004). Most
melanocytic nevi do not progress to melanoma (Omholt
et al., 2003; Pollock et al., 2003; Uribe et al., 2003; Yazdi
et al., 2003; Saldanha et al., 2004). Furthermore, the
prognostic significance of BRAF mutational status is some-
what controversial, but most studies do not show a significant
link with outcome (Kumar et al., 2003; Chang et al., 2004;
Shinozaki et al., 2004). If BRAF mutation is indeed required
for tumorigenesis, additional changes must accumulate for
tumor progression and we need to understand mutations that
occur in conjunction with BRAF.
Our previous analysis of melanoma cell lines and the work
of Davies and others show that cell lines that harbor BRAF
mutations do not have NRAS mutations (Tsao et al., 2000;
Davies et al., 2002). Although complete reciprocity is not
universal, these findings suggest that activation is required at
only one point in the rat sarcoma oncogene (RAS)/V-raf-1
murine leukemia viral oncogene homolog (RAF)/mitogen-
activated protein kinase (MAPK) pathway to activate the
downstream targets and initiate cell proliferation and/or
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tumorigenesis (Kumar et al., 2003; Pollock et al., 2003).
These data are borne out in studies of excised melanocytic
nevi and primary and metastatic melanoma samples as well.
The tumor suppressor PTEN was found to be mutated in
melanoma cell lines at a rate of 30–50% (Guldberg et al.,
1997; Tsao et al., 1998; Whiteman et al., 2002), but rates
were lower in primary cutaneous melanoma in some studies
(Poetsch et al., 2001; Pollock et al., 2003). Loss of PTEN
activity, through deletion, mutation, or reduced expression,
results in signaling through PIP3, activation of Akt, and
interference with apoptosis (reviewed by Wu et al., 2003).
Previously, we observed that, as is true for NRAS and
BRAF, NRAS mutations and PTEN inactivation are reciprocal
in at least a subset of melanoma cell lines (Tsao et al., 2000).
One would expect not to observe concurrent mutation of
NRAS and PTEN if they act in series in the PI3K/Akt signaling
pathway. We propose that this is the case in melanoma, that
mutations of the PTEN/AKT pathway render NRAS mutation
redundant, and that NRAS mutation and PTEN loss will be
distributed reciprocally. This hypothesis, generated from cell
line data, has not been tested in primary melanoma samples.
We examined 69 micro-dissected, formalin-fixed primary
cutaneous melanomas that were enriched for thick melanomas
in an effort to further examine the roles of BRAF, NRAS, and
PTEN in NRAS in primary cutaneous melanoma progression.
We evaluated the mutational status of NRAS and BRAF by
DNA analysis and PTEN expression by immunohistochemistry.
RESULTS
A total of 69 formalin-fixed paraffin-embedded primary
melanoma samples were examined. Limited demographic
and histologic data, tumor site, and BRAF, NRAS, and Pten
status for each sample are presented in Table 1. The patient
population included 41 females (59%) and 28 males (41%).
Ages ranged from 16 to 91 years, with a mean age of 58.3 years
(median, 58 years). In all, 21 tumors were in the head and neck
region, eight were from the upper extremities, 21 from the
lower extremities, 16 were from the back/trunk, and three from
mucosal sites. The Breslow thickness ranged from 0.4 to
16.0 mm, with a median of 1.70 mm (mean of 3.78 mm). The
majority of cases were of the superficial spreading type (n¼ 45;
65%), with the remaining being nodular (n¼ 7; 10%), acral
lentiginous (n¼ 5; 7%), lentigo maligna/desmoplastic (n¼ 6;
9%), mucosal (n¼3; 4%), or other/unclassified (n¼ 3; 4%).
Altogether, 16 samples did not yield amplifiable DNA for
at least one of the PCR analyses: seven failed BRAF PCR
alone, four failed both BRAF and NRAS PCR, and five failed
NRAS PCR alone. These samples showed a trend (P¼0.1065)
towards being thicker melanomas (mean thickness 5.20 mm;
median 3.85 mm).
Amplification of BRAF by PCR was successful in 58
samples and 33 (57%) revealed the BRAFV600E mutation. Of
the 33 B-RAFV600E mutations, 22 (67%) were seen in tumors
less than or equal to 2.0 mm in thickness. BRAF mutational
status was significantly associated with tumor thickness for
all melanoma types (P¼ 0.0273), but was not significantly
associated if only superficial spreading type is considered
(P¼0.6873). BRAF mutational status was significantly
associated with younger patient age in the entire popula-
tion (P¼ 0.0212, r 2¼0.0912), but this association was not
present when only superficial spreading type was considered
(P¼0.3526).
Exon 2 of NRAS was amplified in 60 samples and 10
activating mutations (17%) at amino-acid position 61 were
noted. No mutations in exon 1 of NRAS were seen in the 51
samples where amplification was successful. In all, 53
samples were assessable for both BRAF and NRAS exon 2;
among these, 38 or 72% carried a BRAF and/or NRAS
mutation. Activating mutations in NRAS showed no discern-
able correlation with tumor thickness (P¼0.6640) or any of
the other variables, with the exception of age (P¼0.0238).
Older patient age was associated with mutations.
Of the 33 tumors with mutations in BRAF, 30 were also
assessable for NRAS and only two showed concurrent
mutation of NRAS. In the 53 tumors assessable with regard
to both genes, BRAF and NRAS were significantly associated
(P¼0.0138) as 93% of those tumors with mutant BRAF had
wild-type NRAS2 versus 65% of those with wild-type BRAF
who had wild-type NRAS2. In general, BRAF and NRAS2
mutations were mutually exclusive.
Immunohistochemistry revealed that Pten was completely
absent (three cases) or reduced by greater than 50% (10
cases) in 13 (19%) of the 69 tumors. In all, 11 of the 13
tumors with reduced/absent Pten expression by immunohis-
tochemistry occurred in tumors greater than 3.5 mm in
thickness; loss or reduction of Pten expression was signifi-
cantly associated with increased tumor thickness in the entire
population (Spearman r¼0.46, Po0.0001) and this asso-
ciation held when only superficial spreading tumors were
considered (Spearman r¼0.33, P¼ 0.0274). None of the
10 tumors with NRAS mutations showed reduced expression
of Pten. Of the 13 tumors with reduced/absent Pten
expression, seven could be amplified for BRAF and three of
these harbored BRAF mutations. The inability to amplify
BRAF in six of the 13 Pten reduced/loss cases did not allow
further analysis of relationships.
DISCUSSION
We observed that there was an overlap between Pten loss/
reduction and BRAF mutation, although it was not possible to
comment on the significance of the relationship as only seven
of the 13 cases with abnormal Pten expression yielded
amplifiable material for BRAF analysis. One might be
concerned that the loss of Pten expression and the
concordant lack of BRAF DNA of sufficiently high quality
to amplify might be due to tissue degradation; however, in all
but two the DNA was amplifiable for the NRAS gene. This
argues that the loss of Pten expression was in fact biological,
and not an artifact. In addition, these cases all showed intact
staining of PTEN in the endothelial cells of tumor-associated
vessels. However, we cannot exclude poor DNA quality as
explanation for BRAF PCR failure.
We examined the relationship between alteration in these
three genes in melanoma cell lines (Tsao et al., 2000). We
found that, in cell lines, concurrent mutation of BRAF and
loss of PTEN, with alteration of the MAPK and PI3K/Akt
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Table 1. Primary cases of invasive melanoma with clinical parameters and relationships between pathway
mutations and PTEN loss
Sample Gender Age Sites Breslow Type/Clark PTEN BRAF NRAS
Genotype: BRAF mutation only
44 M 71 Back 0.44 SS/III +++ MUT wt
50 F 54 Back 0.4 SS/II ++ MUT wt
46 M 50 Back 0.44 SS/III ++ MUT wt
57 F 46 Shoulder 0.5 SS/II ++ MUT wt
62 M 47 Back 0.5 SS/II +++ MUT wt
36 F 51 Forearm 0.62 SS/III ++ MUT wt
2 F 26 Thigh 0.6 SS/III ++ MUT wt
35 F 54 Leg 0.6 SS/III ++ MUT wt
51 M 47 Thigh 0.66 SS/IV ++ MUT wt
38 M 32 Cheek 0.68 SS/II ++ MUT wt
29 F 52 Leg 0.8 SS/IV ++ MUT wt
41 F 57 Thigh 0.8 SS/IV +++ MUT wt
42 F 29 Mons pubis 0.88 SS/IV ++ MUT wt
32 F 37 Arm 0.99 SS/IV ++ MUT wt
4 M 78 Cheek 1.1 SS/IV ++ MUT wt
53 F 86 Leg 1.2 SS/IV ++ MUT wt
61 F 76 Arm 1.7 SS/IV ++ MUT wt
7 M 63 Shoulder 2 N/IV ++ MUT wt
34 F 43 Ankle 2.2 SS/IV +++ MUT wt
24 M 45 Flank 2.32 SS/IV +++ MUT wt
13 M 71 Abdomen 2.5 SS/IV ++ MUT wt
66 F 42 Neck 3 D/IV ++ MUT wt
10 F 64 Foot 4 AL/IV ++ MUT wt
21 F 43 Finger 4.15 D/IV ++ MUT wt
26 F 21 Back 12 SS/V ++ MUT wt
Genotype: NRAS mutation only
58 F 53 Forearm 0.4 SS/IV +++ wt MUT
5 M 76 Calf 0.66 SS/IV ++ wt MUT
8 M 76 Leg 0.66 LM/D V ++ wt MUT
25 F 82 Heel 5 N/IV ++ wt MUT
14 F 43 Scalp 7 U(mb) V ++ wt MUT
23 M 72 Shoulder 7.3 N/IV ++ wt MUT
22 M 91 Ear 10 UV ++ wt MUT
12 M 81 Forehead 15 LM/D V ++ wt MUT
Genotype: BRAFand NRAS mutation
31 F 55 Neck 0.46 SS/III +++ MUT MUT
40 F 80 Back 0.85 SS/IV ++ MUT MUT
Genotype: BRAF and NRAS wt
69 F 25 Leg 0.4 SS/II ++ wt wt
60 F 72 Arm 0.55 SS/III ++ wt wt
Table 1 continued on following page
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pathways, respectively, recapitulate the same downstream
biochemical effects of NRAS mutation. Although hampered
by the lack of amplification in a small subset of our samples,
our data indicate that concurrent alteration of both pathways,
in the absence of NRAS mutations, occurs in primary tumors,
as we demonstrated previously. This is an important
confirmation of the significance of the results from melanoma
cell lines, most of which are derived from metastatic
Table 1. continued
Sample Gender Age Sites Breslow Type/Clark PTEN BRAF NRAS
37 M 91 Neck 0.66 SS/IV +++ wt wt
6 F 58 Breast 0.7 SS/IV ++ wt wt
54 F 48 Back 1.3 SS/IV +++ wt wt
59 F 68 Heel 1.3 AL III ++ wt wt
67 M 69 Finger 3.6 AL IV ++ wt wt
68 F 16 Ear 3.7 SS/IV +++ wt wt
63 M 80 Forehead 6 LM/D V ++ wt wt
3 F 45 Foot 6.2 AL IV ++ wt wt
9 M 76 Ear 10 D V ++ wt wt
Sample Gender Age Sites Breslow
Type/Other/
Clark PTEN BRAF NRAS
Genotype: PTEN loss and evaluable BRAF and NRAS
11 F 73 Forehead 0.9 SS/III + wt wt
17 F 71 Clitoris 4.3 M/NA  wt wt
28 F 82 Cheek 4.5 N/IV + wt wt
52 M 58 Back 5 SS/V + MUT wt
20 M 50 Scalp 7.5 U/V + MUT wt
45 F 79 Ankle 15 SS/V  MUT wt
15 F 90 Vagina 13.5 M/NA  wt wt
No amplification of BRAF and/or NRAS (16/69 (23%) mean Breslow=5.2 mm)
1 M 58 Back 9 N/V + na na
16 F 79 Clitoris 12 M/N/A ++ na na
18 F 65 Foot 14 N/IV + na na
19 M 30 Toe 2.67 AL/IV ++ na wt
27 M 29 Back 6.2 SS/IV + na na
30 M 49 Scalp 3.85 SS/IV  na wt
33 F 36 Calf 0.75 SS/IV ++ na wt
39 M 81 Arm 1.55 N/III ++ MUT na
43 M 74 Leg 1.55 SS/IV +++ na wt
47 F 58 Cheek 8 SS/V + na wt
48 F 57 Back 0.5 SS/III ++ MUT na
49 F 78 Calf 1 SS/III + na wt
55 F 60 Cheek 16 LM/D V ++ wt na
56 M 38 Knee 0.5 SS/IV ++ na wt
64 F 45 Ear 2.4 SS/IV ++ MUT na
65 M 43 Back 3.2 N/III ++ wt na
Sample: case number; gender: F, female; M, male; age, age in years; site: site of tumor; type, melanoma subtype; AL, acral lentiginous type; D, desmoplastic
type; LM/D, lentigomaligna/desmoplastic type; M, mucosal type; N, nodular type; SS, superficial spreading type; U, unclassified type; U(mb), malignant blue
nevus; Clark, Clark level; Breslow (mm): Breslow thickness expressed in mm; PTEN, result of immunohistochemistry for PTEN; BRAF, results of mutational
screen for BRAF at V600E; NRAS2, results of mutational screening at NRAS exon 2; MUT: mutation; wt, wild-type; na, not amplified.
www.jidonline.org 157
V Goel et al.
Examination of BRAF in Primary Melanoma
melanoma samples and have passed through many genera-
tions in vitro.
We observed a highly significant relationship between
increasing melanoma thickness and the loss or reduced
expression of Pten. The data seem to suggest a potential
relationship between thin melanomas and BRAF mutation, but
the observation is confounded by the fact that most of the
thicker melanomas were of subtypes where BRAF mutations
are known to be less prevalent, such as acral lentiginous,
desmoplastic, and mucosal melanomas (Sasaki et al., 2004;
Davison et al., 2005). In this study, only superficial spreading
type melanoma (n¼45, 65%) was present in numbers that
allowed for examination of BRAF status within a single
histology. When this was done, there was no relationship
between Breslow thickness and mutation. This is in keeping
with the findings of others. However, the relationship between
loss of or reduced expression of Pten and thicker melanomas
remained highly significant within this single subtype.
Data that provide some understanding as to the sequence
of these multiple events are accumulating. BRAF mutation,
based on its prevalence in studies of otherwise benign
melanocytic nevi, is likely an early event. Parallel PTEN/AKT
pathway involvement may accrue later. This view is
supported by four lines of evidence. First, early PTEN loss,
as occurs in Cowden and related inherited cancer syndromes,
does not confer an increased risk for the development of
melanoma. Second, Tsao et al. (2003) did not report any
significant loss of PTEN expression in benign melanocytic
tumors. Third, our data here suggest a low rate of PTEN loss in
thin primary melanomas (3/36 samples carrying a BRAF
mutation have PTEN loss), and a correlation with increasing
Breslow thickness. Fourth, our cell line data (Tsao et al.,
1998, 2004), in which PTEN loss approximates 30%, may be
explained if PTEN loss is more frequent in the metastatic
melanomas used to initiate the cell lines. We cannot exclude
possible selection for PTEN loss by tissue culture itself. But
taken together, these data suggest PTEN loss, or, perhaps
more generally, AKT pathway abrogation occurs later in
melanoma tumorigenesis. Its contribution to the biological
behavior of the tumor is not yet understood.
In these primary samples, PTEN loss reduction (13 cases) or
NRAS activation (10 cases) was observed in 23/69 or 33% of
tumors. These data underscore the importance of considering
the concurrent presence of abnormalities in both MAPK and
Akt pathways for melanoma tumorigenesis. If PTEN loss does
accumulate with progression, metastatic melanoma will be
expected to exhibit higher rates of AKT pathway abnormalities.
Finally, these genetic findings may have implications for
melanoma therapy, even though our examination here is
limited to primary tumors. Inhibitors of each of these pathways
have singly been tested in the preclinical setting. MAPK
activation in a melanoma cell line was abrogated by the
MAPK/ERK kinase inhibitor PD98059, as well as specific
orally available MAPK inhibitor CI 1040 (Collisson et al.,
2003; Satyamoorthy et al., 2003). Similarly, treatment of
melanoma cell lines with high pAKT levels using PI3-K
inhibitors such as LY294002 or wortmannin has been reported
(Dhawan et al., 2002). In the clinic, the inhibitor of BRAF, BAY
43-9006, has been tested in phase I trials with little single-
agent activity (Strumberg et al., 2005). The data reported here
suggest that alteration of the BRAF-MAPK and PTEN-AKT
occurs frequently, possibly in sequence but often in concert. It
is possible that successful targeted therapy strategies will need
to inhibit both pathways simultaneously to be successful.
MATERIALS AND METHODS
Sample selection
The case files of Brigham and Women’s Hospital, Boston, MA,
spanning 1992–2001 were reviewed for hematoxylin-and-eosin-
stained sections representative of advanced primary cases of invasive
melanoma. We set out to identify all cases with Breslow thickness
greater than 4 mm with paraffin-embedded tissue available from the
time interval. Our goal was to ascertain that all available advanced
primaries, which are rare, were examined in order to compare early/
thin and late/thick primary tumors. Thus, a subset of this study is a
10-year consecutive series of all lesions greater than or equal to
4 mm in Breslow depth. Subsequently, representative lesions with
thickness less than 4 mm and with available paraffin blocks were
randomly chosen in a proportional manner from the same time
period. Cases of melanoma in situ were excluded.
The described studies using human tissue samples were
performed in adherence with the Declaration of Helsinki principles
and under the review and approval of the Partners Human Research
Committee, Assurance #FWA00003136. The tumors were classified
by a dermatopathologist (A.J.F.L.) as superficial spreading, nodular,
acral lentiginous, or lentigo maligna according to established
histopathologic standards. If the invasive component was primarily
desmoplastic, this was also noted. One case of so-called malignant
cellular blue nevus (confirmed by the presence of a regional lymph
node metastasis) was included in the study.
Immunohistochemistry for PTEN
For each case, 4-mm formalin-fixed, paraffin-embedded tissue
sections were stained with hematoxylin and eosin. A section from
a representative paraffin block in each case was also studied by
immunohistochemistry for the Pten protein (monoclonal 6H2.1,
Cascade Biosciences, Winchester, MA) using a modification of a
previously established protocol (Mutter et al., 2001). Briefly, the
slides were deparaffinized and treated with an alcohol gradient to
absolute ethanol. Endogenous peroxidase activity was blocked with
a solution of 1% hydrogen peroxide and 65% ethanol. Antigen
retrieval was performed in Target Retrieval Solution (DAKO
Carpinteria, CA) in a microwave for 30 minutes at 781C. After
cooling for 30 minutes in fresh Target Retrieval Solution, primary
antibody was applied at 1:750 dilution and incubated at 41C
overnight. Anti-mouse IgG with the DAKO Envisionþ detection
system (horseradish peroxidase) was employed as per the manu-
facturer’s directions. If the tumor contained abundant melanin that
interfered with interpretation, the DAKO LSABþ system (alkaline
phosphatase) was substituted. Light hematoxylin was used as
counterstain. Separate positive and negative controls were per-
formed in parallel. Endothelial cells were an important internal
positive control and were present with robust staining in all 69 cases
examined (see Figure 1). Pten immunohistochemistry was inter-
preted independently by two pathologists (AJFL and MR) who
were blinded to the BRAF, RAS mutational status of the cases. A
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previously described system for scoring the staining by comparison
to adjacent endothelial cells in tumor-associated vasculature was
used (Zhou et al., 2000). Scoring included the following categories:
increased (þ þ þ ), equivalent (þ þ ), significantly reduced (þ ),
and absent (). Significantly reduced was defined as less than 50%
of levels in adjacent endothelial cells. A few tumors showed broad
areas of reduced or absent expression in an apparently clonal
distribution, and these were scored as reduced (þ ). These areas of
reduced expression comprised approximately half of the tumors in
the few cases where it was noted.
DNA isolation and mutation detection for NRAS and BRAF
Genomic DNA was extracted as described previously (Tsao et al.,
1998), with minor modifications. Briefly, paraffin was removed from
two or three 10-mm-thick unstained slides from each case by xylene
immersion, washed with isopropanol, and rehydrated with graded
ethanol and water mixtures. The slides were then lightly stained with
hematoxylin (Gill’s formulation #2; Fischer Scientific, Hanover Park,
IL) to aid microdissection and washed in 10 mM Tris, pH¼ 8, and
1 mM EDTA buffer. The melanoma tumor was then manually
microdissected from the stained slides using scalpel blades under
microscopic guidance and incubated with proteinase K in a
100–150 ml aliquot overnight at 551C. Based on this direct
visualization during microdissection, we estimate that all samples
consisted of greater than 80% melanoma cells. The proteinase K was
inactivated by heating the sample to 1001C for 5 minutes. To the
crude DNA extract, 100 ml of the protein extraction (Puregenes,
Gentra Sytsems, Minneapolis, MN) reagent was added, incubated
on ice for 1 hour, and centrifuged to sediment the insoluble fraction.
The supernatant was transferred to a new eppendorf tube and
supplemented with glycogen and 100% ethanol and stored at
801C for 48 hours to precipitate the DNA. The DNA was recovered
after centrifugation at 41C and the pellet was washed once with
ice-cold 70% ethanol. The DNA pellet was air-dried, re-suspended
in 70–80ml Tris buffer (pH 8.0) and used for subsequent PCR
amplification. The primer sets used for the PCR amplification were
as follows:
BRAF, 15F 1 50-TCATAATGCTTGCTCTGATAGGA-30
BRAF, X15R 23 50-GGCCAAAAATTTAATCAGTGGA-30
This pair produces an amplicon of approximately 240 bp.
RmutantFOR, 23, 50-CTAAACTCTTCATAATGCTTGCTC-30
RmutantREV (new primer), 50-CCAGACAACTGTTCAAACTGATG
GGAC-30
This primer pair yields a PCR amplicon of about 176 bp.
For NRAS exon 1 and exon 2 sequencing, primers and conditions
were used as described previously (Omholt et al., 2003).
NRAS-1F, 50-CAG GTT CTT GCT GGT GTG AAA TGA CTG AG-30
NRAS-1R, 50-CTA CCA CTG GGC CTC ACC TCT ATG G-30
The amplicon size is 148 bp.
NRAS, 2F 50-GTT ATA GAT GGT GAA ACC TG-30
NRAS, 2R 50-ATA CAC AGA GGA AGC CTT CG-30
The amplicon size is about 115 bp.
For all PCR reactions, 0.25–2.5ml of extracted DNA was used
with the following PCR conditions:
Initial denaturation at 961C for 10 minutes, followed by 45 cycles
of 961C denaturation for 40 seconds, annealing at 511C for
90 seconds, extension at 721C for 90 seconds, and a final extension
at 721C for 10 minutes.
After PCR amplification, the samples were applied to a 1.2%
agarose gel and eluted and purified using QIAquick Gel Extraction
Kit (QIAGEN, Valencia, CA) as per the manufacturer’s instructions.
Sequencing was performed using an ABI 377 DNA Sequencer
(Applied Biosystems, Foster City, CA) at the Massachusetts General
Hospital DNA sequencing core facility (Boston, MA).
Statistical analysis
Simple univariate descriptive statistics were utilized to describe the
population. For bivariate relationships, proportions were compared
using Fisher’s exact test. Associations between age and categorical
variables were determined using one-way analysis of variance, and
associations between Breslow thickness and categorical variables
were compared using the Wilcoxon rank-sum test normal approx-
imation with continuity correction, or the Kruskal–Wallis test.
Correlations were determined using Spearman’s correlation coeffi-
cient. All tests are two-sided, with a 5% significance level.
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